Botulinum toxin A and neuropathic pain: An update

被引：6

作者：

Spagna, A. ^{[1
]}

Attal, N. ^{[1
,2
,3
]}

机构：

[1] Ambroise Pare Hosp, APHP, CETD, F-92100 Boulogne Billancourt, France

[2] Paris Saclay Univ, Ambroise Pare Hosp, APHP, Inserm,UVSQ,U987, F-92100 Boulogne Billancourt, Paris, France

[3] Hop Ambroise Pare, Ctr Evaluat & Traitement Douleur, INSERM, U987, 9 Ave Charles Gaulle, F-92100 Boulogne Billancourt, France

来源：

TOXICON | 2023年 / 232卷

关键词：

Botulinum toxin a; Neuropathic pain; Narrative review; Mechanisms of action; Trigeminal neuralgia; CAPSAICIN-EVOKED PAIN; DOUBLE-BLIND; TRIGEMINAL NEURALGIA; INJECTIONS; EFFICACY; HYPERALGESIA; VALIDATION; SAFETY; FLARE; MODEL;

D O I：

10.1016/j.toxicon.2023.107208

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Botulinum toxin type A is a widely used neurotoxin for the treatment of muscle hyperactivity such as dystonia and spasticity. Several clinical trials have also reported an efficacy of subcutaneous or intradermal administrations of botulinum toxin A on various neuropathic pain conditions including idiopathic trigeminal neuralgia and found that specific sensory phenotypes were predictors of the response. This narrative review summarizes the potential mechanisms of action, efficacy and safety of botulinum toxin A in neuropathic pain as well as its place in the therapeutic algorithm of neuropathic pain.

引用

页数：5

共 48 条

[1] Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
Aoki, KR
[J]. NEUROTOXICOLOGY, 2005, 26 (05) : 785 - 793
[2] Botulinum Toxin A in Postherpetic Neuralgia A Parallel, Randomized, Double-Blind, Single-Dose, Placebo-controlled Trial
Apalla, Zoe
Sotiriou, Elena
Lallas, Aimilios
Lazaridou, Elizabeth
Ioannides, Demetrios
[J]. CLINICAL JOURNAL OF PAIN, 2013, 29 (10) : 857 - 864
[3] Translational neuropathic pain research
Attal, Nadine
Bouhassira, Didier
[J]. PAIN, 2019, 160 : S23 - S28
[4] Diagnosis and assessment of neuropathic pain through questionnaires
Attal, Nadine
Bouhassira, Didier
Baron, Ralf
[J]. LANCET NEUROLOGY, 2018, 17 (05) : 456 - 466
[5] Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial
Attal, Nadine
de Andrade, Daniel C.
Adam, Frederic
Ranoux, Daniele
Teixeira, Manoel J.
Galhardoni, Ricardo
Raicher, Irina
Ueceyler, Nurcan
Sommer, Claudia
Bouhassira, Didier
[J]. LANCET NEUROLOGY, 2016, 15 (06) : 555 - 565
[6] The specific disease burden of neuropathic pain: Results of a French nationwide survey
Attal, Nadine
Lanteri-Minet, Michel
Laurent, Bernard
Fermanian, Jacques
Bouhassira, Didier
[J]. PAIN, 2011, 152 (12) : 2836 - 2843
[7] Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection
Bach-Rojecky, Lidija
Salkovic-Petrisic, Melita
Lackovic, Zdravko
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 633 (1-3) : 10 - 14
[8] European Academy of Neurology guideline on trigeminal neuralgia
Bendtsen, L.
Zakrzewska, J. M.
Abbott, J.
Braschinsky, M.
Di Stefano, G.
Donnet, A.
Eide, P. K.
Leal, P. R. L.
Maarbjerg, S.
May, A.
Nurmikko, T.
Obermann, M.
Jensen, T. S.
Cruccu, G.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (06) : 831 - 849
[9] Botulinum. toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study
Blersch, W
Schulte-Mattler, WJ
Przywara, S
May, A
Bigalke, H
Wohlfarth, K
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 205 (01) : 59 - 63
[10] Development and validation of the neuropathic pain symptom inventory
Bouhassira, D
Attal, N
Fermanian, J
Alchaar, H
Gautron, M
Masquelier, E
Rostaing, S
Lanteri-Minet, M
Collin, E
Grisart, J
Boureau, F
[J]. PAIN, 2004, 108 (03) : 248 - 257

← 1 2 3 4 5 →